Knocking out CDKN1A promoted cisplatin resistance in ovarian cancer cells, increasing ovarian cancer cell proliferation and decreasing apoptosis in previously cisplatin-sensitive cells. This evidence concerns the gene CDKN1A and ovarian carcinoma.